Latest Breaking News On - Arrowhead pharmaceuticals inc - Page 3 : vimarsana.com

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report released on Monday, Benzinga reports. They currently have a $90.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2028 earnings at $0.43 EPS. A number of other equities analysts […]

United statesHongbo luArrowhead pharmaceuticalsArrowhead pharmaceuticals price performanceSecurities exchange commissionCanada life assuranceArrowhead pharmaceuticals incInstitutional trading of arrowhead pharmaceuticalsPricet rowe associates incAvoro capital advisorsInsider transactions at arrowhead pharmaceuticalsMorgan stanleyNews ratings for arrowhead pharmaceuticals dailyAnalyst recommendations for arrowhead pharmaceuticalsRoyal bankAffinity asset advisors